184 related articles for article (PubMed ID: 33800911)
21. Dinaciclib for the treatment of breast cancer.
Criscitiello C; Viale G; Esposito A; Curigliano G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1305-12. PubMed ID: 25107301
[TBL] [Abstract][Full Text] [Related]
22. The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.
Schoenwaelder N; Salewski I; Engel N; Krause M; Schneider B; Müller M; Riess C; Lemcke H; Skorska A; Grosse-Thie C; Junghanss C; Maletzki C
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34063457
[TBL] [Abstract][Full Text] [Related]
23. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
[TBL] [Abstract][Full Text] [Related]
24. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
25. CDK inhibitors in cancer therapy, an overview of recent development.
Zhang M; Zhang L; Hei R; Li X; Cai H; Wu X; Zheng Q; Cai C
Am J Cancer Res; 2021; 11(5):1913-1935. PubMed ID: 34094661
[TBL] [Abstract][Full Text] [Related]
26. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
Nemunaitis JJ; Small KA; Kirschmeier P; Zhang D; Zhu Y; Jou YM; Statkevich P; Yao SL; Bannerji R
J Transl Med; 2013 Oct; 11():259. PubMed ID: 24131779
[TBL] [Abstract][Full Text] [Related]
27. Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.
Ke C; Hou H; Li J; Su K; Huang C; Lin Y; Lu Z; Du Z; Tan W; Yuan Z
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32375399
[TBL] [Abstract][Full Text] [Related]
28. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
Mounika P; Gurupadayya B; Kumar HY; Namitha B
Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
[TBL] [Abstract][Full Text] [Related]
29. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
[TBL] [Abstract][Full Text] [Related]
30. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
Hu C; Dadon T; Chenna V; Yabuuchi S; Bannerji R; Booher R; Strack P; Azad N; Nelkin BD; Maitra A
Mol Cancer Ther; 2015 Jul; 14(7):1532-9. PubMed ID: 25931518
[TBL] [Abstract][Full Text] [Related]
31. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
[TBL] [Abstract][Full Text] [Related]
32. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
[TBL] [Abstract][Full Text] [Related]
33. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma.
Shao YY; Li YS; Hsu HW; Lin H; Wang HY; Wo RR; Cheng AL; Hsu CH
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561409
[TBL] [Abstract][Full Text] [Related]
34. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
[TBL] [Abstract][Full Text] [Related]
35. Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells.
Xu L; Li L; Zhang J; Cai W; Zhao S; Liu S
Odontology; 2020 Apr; 108(2):300-311. PubMed ID: 31529315
[TBL] [Abstract][Full Text] [Related]
36. Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells.
Riess C; Del Moral K; Fiebig A; Kaps P; Linke C; Hinz B; Rupprecht A; Frank M; Fiedler T; Koczan D; Troschke-Meurer S; Lode HN; Engel N; Freitag T; Classen CF; Maletzki C
Cell Death Dis; 2022 Jun; 13(6):555. PubMed ID: 35717443
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
[TBL] [Abstract][Full Text] [Related]
38. Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors.
Sofi S; Mehraj U; Qayoom H; Aisha S; Almilaibary A; Alkhanani M; Mir MA
Med Oncol; 2022 Jun; 39(9):133. PubMed ID: 35723742
[TBL] [Abstract][Full Text] [Related]
39. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
